Therapeutic Area | MeSH |
---|---|
urogenital diseases | D000091642 |
mental disorders | D001523 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ZULRESSO | Sage Therapeutics | N-211371 DISCN | 2019-06-17 | 1 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
zulresso | New Drug Application | 2024-07-17 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
postpartum depression | EFO_0007453 | D019052 | F53.0 |
Expiration | Code | ||
---|---|---|---|
BREXANOLONE, ZULRESSO, SAGE THERAP | |||
2025-06-16 | NPP | ||
2024-06-17 | NCE |
Code | Description |
---|---|
J1632 | Injection, brexanolone, 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Postpartum depression | D019052 | EFO_0007453 | F53.0 | — | 2 | 3 | 2 | 2 | 9 |
Depression | D003863 | — | F33.9 | — | 2 | 3 | 1 | 2 | 8 |
Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 2 | 3 | 1 | 2 | 8 |
Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | 1 | 1 | — | 1 | — | 3 |
Traumatic stress disorders | D040921 | — | — | — | 1 | — | 1 | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Status epilepticus | D013226 | EFO_0008526 | G41 | 1 | 1 | 1 | — | 1 | 3 |
Covid-19 | D000086382 | — | U07.1 | — | — | 1 | — | — | 1 |
Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | 1 | — | — | 1 |
Acute lung injury | D055371 | EFO_0004610 | — | — | — | 1 | — | — | 1 |
Newborn respiratory distress syndrome | D012127 | — | P22 | — | — | 1 | — | — | 1 |
Syndrome | D013577 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Alcoholism | D000437 | EFO_0003829 | F10.1 | 1 | 1 | — | — | — | 2 |
Alcohol drinking | D000428 | EFO_0004329 | — | 1 | 1 | — | — | — | 2 |
Essential tremor | D020329 | EFO_0003108 | G25.0 | — | 1 | — | — | — | 1 |
Tremor | D014202 | — | R25.1 | — | 1 | — | — | — | 1 |
Tinnitus | D014012 | — | H93.1 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Psychotic disorders | D011618 | — | F20.81 | 1 | — | — | — | — | 1 |
Mental disorders | D001523 | EFO_0000677 | F91.9 | 1 | — | — | — | — | 1 |
Drug common name | Brexanolone |
INN | brexanolone |
Description | Brexanolone is a 3-hydroxy-5alpha-pregnan-20-one in which the hydroxy group at position 3 has alpha-configuration. It is a metabolite of the sex hormone progesterone and used for the treatment of postpartum depression in women. It has a role as a human metabolite, an antidepressant, a GABA modulator, an intravenous anaesthetic and a sedative. |
Classification | Small molecule |
Drug class | steroids (not prednisolone derivatives) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |
PDB | — |
CAS-ID | 516-54-1 |
RxCUI | — |
ChEMBL ID | CHEMBL207538 |
ChEBI ID | 50169 |
PubChem CID | 92786 |
DrugBank | DB11859 |
UNII ID | S39XZ5QV8Y (ChemIDplus, GSRS) |